Suppr超能文献

单链抗体M6-1B9胞内抗体下调细胞外基质金属蛋白酶诱导因子通过抑制尿激酶型纤溶酶原激活剂抑制宫颈癌侵袭。

Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.

作者信息

Panich Tipattaraporn, Tragoolpua Khajornsak, Pata Supansa, Tayapiwatana Chatchai, Intasai Nutjeera

机构信息

1 Division of Clinical Microscopy, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University , Chiang Mai, Thailand .

2 Division of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University , Chiang Mai, Thailand .

出版信息

Cancer Biother Radiopharm. 2017 Feb;32(1):1-8. doi: 10.1089/cbr.2016.2126. Epub 2017 Jan 24.

Abstract

Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN) accelerates tumor invasion and metastasis via activation of matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA) expression. The authors were interested in whether the scFv-M6-1B9 intrabody against EMMPRIN that retains EMMPRIN in endoplasmic reticulum could be a potential tool to suppress cervical cancer invasion through inhibition of uPA. The chimeric adenoviral vector Ad5/F35-scFv-M6-1B9 was transferred into human cervical carcinoma HeLa cells to produce the scFv-M6-1B9 intrabody against EMMPRIN. Cell surface expression of EMMPRIN, the membrane-bound uPA, the enzymatic activity of secreted uPA, and the invasion ability were analyzed. The scFv-M6-1B9 intrabody successfully diminished the cell surface expression of EMMPRIN and the membrane-bound uPA on HeLa cells. uPA activity from tissue culture media of EMMPRIN-downregulated HeLa cells was decreased. The invasion ability of HeLa cells harboring scFv-M6-1B9 intrabody was also suppressed. These results suggested that the scFv-M6-1B9 intrabody might represent a potential approach for invasive cervical cancer treatment. The application of scFv-M6-1B9 intrabody in animal experiments and preclinical studies would be investigated further.

摘要

细胞外基质金属蛋白酶诱导剂(EMMPRIN)的过表达通过激活基质金属蛋白酶(MMPs)和尿激酶型纤溶酶原激活剂(uPA)的表达来加速肿瘤侵袭和转移。作者感兴趣的是,针对EMMPRIN的单链抗体片段(scFv)-M6-1B9胞内抗体,可将EMMPRIN保留在内质网中,是否可能成为通过抑制uPA来抑制宫颈癌侵袭的潜在工具。将嵌合腺病毒载体Ad5/F35-scFv-M6-1B9转入人宫颈癌HeLa细胞,以产生针对EMMPRIN的scFv-M6-1B9胞内抗体。分析了EMMPRIN的细胞表面表达、膜结合uPA、分泌型uPA的酶活性以及侵袭能力。scFv-M6-1B9胞内抗体成功降低了HeLa细胞表面EMMPRIN和膜结合uPA的表达。EMMPRIN下调的HeLa细胞组织培养基中的uPA活性降低。携带scFv-M6-1B9胞内抗体的HeLa细胞的侵袭能力也受到抑制。这些结果表明,scFv-M6-1B9胞内抗体可能是治疗侵袭性宫颈癌的一种潜在方法。scFv-M6-1B9胞内抗体在动物实验和临床前研究中的应用将进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验